EUCR Eucrates Biomedical Acquisition Corporation

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

 

(Check One):	¨   Form 10-K	¨   Form 20-F	¨   Form 11-K	x    Form 10-Q
	¨   Form 10-D	¨   Form N-CEN	¨   Form N-CSR

 

      For Period Ended:        March 31, 2022                                                               

 

¨      Transition Report on Form 10-K	¨      Transition Report on Form 11-K
¨      Transition Report on Form 20-F	¨      Transition Report on Form 10-Q

 

For the Transition Period Ended: ______________________________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _____________________________________________________

 

PART I
REGISTRANT INFORMATION

 

Eucrates Biomedical Acquisition Corp.

Full Name of Registrant

N/A

Former Name if Applicable

250 West 55th Street, Suite 13D

Address of Principal Executive Office (Street and Number)

New York, NY 10019

City, State and Zip Code

 

 

 

PART II

RULE 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).

 

	(a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x	(b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III

NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Eucrates Biomedical Acquisition Corp. (the “Company”), has determined that it is unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 (the “Quarterly Report”) with the U.S. Securities Exchange Commission (the “SEC”) by the prescribed due date without unreasonable effort or expense. The Company is still finalizing the accounting presentation relating to the promissory note that it issued to Eucrates LLC on January 20, 2022, which will be reflected in its unaudited financial statements as of and for the fiscal quarter ended March 31, 2022 included in the Quarterly Report. The Company is working diligently to complete the Quarterly Report as soon as practicable and expects to file the Quarterly Report within five calendar days of the prescribed due date.

 

PART IV

OTHER INFORMATION

 

(1)       Name and telephone number of person to contact in regard to this notification

 

Gonzalo Cordova	(212)	710-5220
(Name)	(Area Code)	(Telephone Number)

 

(2)       Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

x         Yes

¨         No

 

(3)       Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

¨         Yes

x         No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

                                   Eucrates Biomedical Acquisition Corp.                                   

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:     May 16, 2022	By:	/s/ Gonzalo Cordova
	Name:	Gonzalo Cordova
	Title:	Chief Financial Officer